Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RVMDthis companyRevolution Medicines, Inc.	$196.80	-13.39×	9.28×	0×	-13.68×	-99.5%	0.0%	0.0%	0.0%	-69.3%	-56.8%	-6.0%	0.1×	0.21×	-48.8×	7.14×	0.0%	1	12.52	1	C-
BDTXBlack Diamond Therapeutics, Inc.	$1.85	6.23×	1.23×	1.97×	5.99×	520.8%	99.5%	28.4%	32.0%	19.9%	15.2%	21.4%	0.17×	-0.1×	0×	8.42×	0.0%	1	-3.44	3	B-
ELVNEnliven Therapeutics, Inc.	$50.90	-8.42×	1.9×	0×	-7.48×	-96.2%	0.0%	0.0%	0.0%	-22.6%	-26.0%	-8.1%	0×	0.95×	0×	28.66×	0.0%	2	130.13	2	C+
ERASErasca, Inc.	$15.30	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
GLUEMonte Rosa Therapeutics, Inc.	$10.46	-26.58×	4.41×	8.31×	-29.87×	222.9%	93.2%	-43.8%	-31.2%	-16.6%	-13.6%	-2.7%	0.17×	2.89×	0×	6.12×	0.0%	2	1.69	2	C+
IDYAIDEAYA Biosciences, Inc.	$31.92	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
Peer median	—	-8.45×	2.99×	1.97×	-8.47×	-96.2%	0.0%	0.0%	0.0%	-16.6%	-15.2%	-2.7%	0.14×	0.55×	0×	10.04×	0.0%	1	14.74	2	—